May 11, 2026
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of the endogenous Growth Hormone-Releasing Hormone (GHRH). Research indicates that this peptide is a potent growth hormone secretagogue, specifically engineered to extend the half-life of GHRH from minutes to several days. By incorporating the DAC technology, the peptide binds covalently to circulating albumin after administration, allowing for a sustained release and a prolonged stimulatory effect on the anterior pituitary gland. (1)
Preclinical investigations focus on its ability to increase plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels without significantly altering the natural pulsatile secretion of GH, making it a primary subject for research in anti-aging, muscle tissue repair, and metabolic optimization.
What is the mechanism by which CJC-1295 with DAC exerts its effects?
The primary mechanism underlying the action of CJC-1295 with DAC involves the activation of the GHRH receptors in the pituitary gland. Unlike standard GHRH, the addition of the Drug Affinity Complex allows the peptide to evade rapid enzymatic degradation.
Upon introduction into a research model, CJC-1295 with DAC appears to:
- Stimulate Somatotrophs: It binds to the GHRH receptors on somatotropic cells, triggering the release of stored growth hormone.
- Sustain IGF-1 Elevation: Due to its long half-life, it provides a consistent signal to the liver to produce IGF-1, which is the primary mediator of the anabolic effects of growth hormone. (2)
- Preserve Pulsatility: While it increases the “basal” level of GH, research suggests it preserves the body’s natural pulsatile GH release, avoiding the total “bleed” effect associated with some other secretagogues.
- Promote Nitrogen Retention: By elevating GH/IGF-1 levels, it facilitates increased nitrogen retention and protein synthesis within musculoskeletal tissues. (3)
The Importance of the DAC (Drug Affinity Complex)
The “DAC” modification is the defining characteristic of this research peptide. Natural GHRH is rendered inactive within minutes by enzymes such as dipeptidyl peptidase-4 (DPP-4). By attaching a reactive group that binds to the cysteine-34 residue on albumin, the peptide becomes part of a much larger, more stable complex.
This modification extends the half-life from approximately 7 minutes to over 6 to 8 days. For research purposes, this allows for once-weekly administration while maintaining stable, elevated levels of GH and IGF-1, providing a unique model for studying chronic growth hormone stimulation without the peaks and valleys of shorter-acting peptides like CJC-1295 No DAC (Mod GRF 1-29). (4)
Research Studies on CJC-1295 with DAC
CJC-1295 and Long-Term GH/IGF-1 Regulation
The efficacy of CJC-1295 with DAC was investigated in healthy research subjects to observe its impact on the GH-axis. Results indicated that a single administration could increase mean plasma GH concentrations by 2-to-10-fold for up to 6 days, and mean plasma IGF-1 concentrations by 1.5-to-3-fold for up to 14 days. Researchers noted that the peptide was well-tolerated and showed high specificity for growth hormone stimulation. (5)
Impact on Fat Metabolism and Lean Mass
This study aimed to investigate the body composition changes in research models under sustained GHRH stimulation. Results suggested that the elevated IGF-1 levels promoted by CJC-1295 with DAC led to an increase in lipolysis (fat loss) and a simultaneous increase in muscle protein synthesis. Mechanistically, the peptide appears to “repartition” nutrients toward muscle tissue and away from adipose stores. (6)
Synopsis
CJC-1295 with DAC appears to be a robust tool for investigating long-term growth hormone dynamics. By utilizing DAC technology to overcome the limitations of natural GHRH stability, it provides a specialized route for studying tissue regeneration, metabolic enhancement, and the physiological effects of sustained IGF-1 elevation. Further research is required to fully understand the impact of prolonged somatotroph stimulation on overall endocrine balance.
NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
CJC-1295 with DAC 5mg – Albumin Binding & Extended Plasma Half-Life Research
A high-stability GHRH analog with extended half-life. Optimized for research into sustained growth hormone elevation, metabolic performance, and long-term tissue maintenance studies.
